Understanding diversity in disease - new routes to prevention, diagnosis and treatment
November 17th, 2007 Posted by: Dr. Dobson
An anti-psychotic drug already approved in the U.S. to treat adults and adolescents with schizophrenia may soon be available for youngsters age 10 to 17 years of age suffering from bipolar disorder.
The U.S. Food and Drug Administration (FDA) has given priority review status to the drug Abilify which is manufactured by Bristol-Myers Squibb and Otsuka Pharmaceutical.
Popularity: unranked [?]
Tags: Understanding, diversity, disease, routes, prevention, diagnosis, treatment